koto_feja/E+ via Getty Images
Biogen (NASDAQ:BIIB) reported that the U.S. FDA has declined to accept its request for a supplemental marketing authorization for a higher dose of Spinraza (nusinersen), a treatment for spinal muscular atrophy.
The agency’s complete response letter indicated that Biogen needs
